Most 'immune tolerant' hepatitis B patients became immune active within a few years

Design

International multicentre observational cohort (RADICAL consortium), median follow-up 13 years

Population

951 strictly defined immune-tolerant patients with chronic hepatitis B, median age 33

Primary outcome

Transition to immune-active disease (ALT 50 U/L or more); fibrosis progression; hepatocellular carcinoma

Effect

Transition 51%, 67% and 72% at 5, 10 and 15 years; ALT above 30 U/L sHR 3.13; fibrosis 6.3% and HCC 1.1% at 15 years

RADICAL is an international consortium cohort of patients with chronic hepatitis B. The immune-tolerant phase was defined strictly: persistently HBeAg-positive, ALT at or below 40 U/L, HBV DNA above 7 log10 IU/mL and fibrosis stage F0 to F1 in the first year. The 951 patients had a median age of 33 and were followed for a median of 13 years.

The probability of moving to immune-active disease (ALT of 50 U/L or more) was 51% by 5 years, 67% by 10 years and 72% by 15 years. A high-normal ALT predicted transition: subdistribution hazard ratio 1.744 for ALT 20 to 30 U/L and 3.130 above 30 U/L, compared with lower values. Progression to significant fibrosis was 6.3% and to hepatocellular carcinoma 1.1% by 15 years.

The low fibrosis and cancer rates suggest the phase is indeed relatively benign, but it is rarely stable. The authors suggest patients with high-normal ALT may benefit from more frequent monitoring or pre-emptive treatment. This is an observational study and does not change current guideline treatment thresholds. Indian guidelines for the immune-tolerant phase have their own criteria, and treatment decisions belong with the liver team.

• Monitor ALT and HBV DNA regularly in immune-tolerant patients; most will change phase within years.
• Treat an ALT of 20 to 30 U/L or higher within the 'normal' range as a reason for closer follow-up.
• Assess fibrosis periodically with elastography or biomarkers.
• Continue HCC surveillance according to your guideline's risk criteria.
• Discuss pre-emptive treatment with a hepatologist; this study does not change guideline thresholds.

Why it matters

It challenges the idea that immune-tolerant disease is a stable state needing only occasional checks.

Don't overread it

This is an observational cohort that does not show that earlier treatment improves outcomes, and guideline thresholds for starting therapy have not changed.

The statistics, in plain English

A transition probability of 67% at 10 years means two in three patients had left the immune-tolerant phase by then. A subdistribution hazard ratio of 3.13 means that, at any time, patients with ALT above 30 U/L were about three times as likely to transition as the reference group. The fibrosis and cancer rates are low in absolute terms, 6.3% and 1.1% over 15 years.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.